Vyleesi Side Effects, Withdrawal, and Discontinuation Syndrome: What Patients and Prescribers Need to Know

What Is Bremelanotide and How Was It Approved?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that binds MC1R, MC3R, MC4R, and MC5R. AMAG Pharmaceuticals received FDA approval on June 21, 2019, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved dose is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per week recommended.

Mechanism Relevant to Side Effects

MC4R agonism drives the drug's central pro-sexual effect but simultaneously activates hypothalamic pathways that control blood pressure and nausea. MC1R activity produces the skin pigmentation changes observed with repeated dosing. Understanding which receptor drives which adverse event helps clinicians counsel patients before the first injection. The FDA prescribing information for Vyleesi specifies these receptor-mediated effects directly (FDA label, accessdata.fda.gov).

The RECONNECT Trial Program

The two key Phase 3 trials, RECONNECT Study 1 and RECONNECT Study 2, enrolled a combined 1,267 premenopausal women with HSDD confirmed by the Diagnostic and Statistical Manual of Mental Disorders criteria. Participants received bremelanotide or placebo as needed over 24 weeks. Adverse event data from these trials form the primary evidence base for everything discussed below (Clayton AH et al., J Sex Med 2016). The published 24-week results showed the drug produced statistically significant increases in satisfying sexual events and desire scores compared with placebo, establishing the benefit side of the risk-benefit equation.

Common Adverse Events: Frequency, Onset, and Duration

Nausea

Nausea is the most frequently reported adverse event. Across the RECONNECT pooled data, approximately 40% of bremelanotide-treated women reported nausea compared with 1% of placebo recipients. Most episodes begin within 30 minutes of injection, peak between 30 and 60 minutes, and resolve within 1 to 2 hours without intervention. Severity is mild to moderate in the majority of cases. In the key trials, 18% of patients used an antiemetic to manage nausea (Kingsberg SA et al., Obstet Gynecol 2019).

Pre-treating with 8 mg ondansetron orally 1 hour before injection reduced nausea rates in post-market clinical experience, though this combination is off-label. The FDA label does not mandate antiemetic prophylaxis but notes the option.

Flushing

Flushing occurred in approximately 20% of treated patients in RECONNECT. Episodes typically appear within minutes of injection and involve the face, neck, and upper chest. Duration ranges from 15 minutes to 1 hour. Flushing alone rarely drives discontinuation.

Injection-Site Reactions

Localized injection-site pain, bruising, and transient induration were reported in about 13% of bremelanotide users. Rotating injection sites between the abdomen and thigh reduces local accumulation of tissue irritation.

Headache

Headache affected roughly 11% of patients on active drug versus 4% on placebo. The mechanism likely involves vasodilation secondary to MC receptor activation. Onset follows the same 30-to-60-minute window as nausea.

Cardiovascular Effects: The Transient Blood Pressure Rise

This is the adverse event that carries the most clinical weight. After a 1.75 mg subcutaneous dose, mean systolic blood pressure rises approximately 6 mmHg and diastolic approximately 3 mmHg, peaking at 1 hour post-dose and returning to baseline by 12 hours. In Phase 2 dose-finding studies, higher doses (4 mg, 7 mg) produced larger and more sustained elevations, which drove the selection of 1.75 mg as the approved dose (Portman DJ et al., J Sex Med 2019).

Who Is at Highest Risk?

Patients with known cardiovascular disease, uncontrolled hypertension, or a history of stroke carry disproportionate risk from even a transient pressure rise. The FDA label lists cardiovascular disease as a contraindication. Patients with well-controlled hypertension should have a baseline blood pressure reading before starting bremelanotide and discuss the risk with their prescriber. The American Heart Association's guidance on drug-induced hypertension is relevant context for this discussion (Vongpatanasin W, AHA/ACC 2019).

Monitoring Approach

No continuous monitoring is required for healthy women meeting label criteria. Prescribers should confirm blood pressure is below 130/80 mmHg at baseline. A single post-dose check during the first use is reasonable clinical practice, particularly for patients with a personal or family history of hypertension.

Hyperpigmentation with Repeated Use

Hyperpigmentation of the face, breasts, and gingiva was reported in 1% of subjects in the RECONNECT trials. This reflects MC1R agonism driving melanocyte stimulation. The label specifies that the condition may not fully resolve after stopping the drug. Patients with darker Fitzpatrick skin types may be at higher risk. Because the label recommends no more than one dose per week, the cumulative MC1R exposure is limited compared with earlier, higher-dose investigational regimens. Dermatology consultation is appropriate if persistent or worsening pigmentation develops (Hwa C and Bhatt D, JAMA Dermatol 2020).

Discontinuation Rates and Reasons

In the pooled RECONNECT data, 8.9% of bremelanotide-treated patients discontinued due to adverse events, compared with 1.3% in the placebo group. Nausea was the leading driver of treatment discontinuation, accounting for a substantial majority of AE-related stops. The separation between active and placebo discontinuation rates is clinically meaningful but not unusual for a drug with a known nausea mechanism (Simon JA et al., Menopause 2019).

Patients who discontinued reported no specific rebound symptoms beyond return of their baseline HSDD, which is the condition being treated, not a drug-induced withdrawal phenomenon.

Does a Withdrawal or Discontinuation Syndrome Exist?

Defining Withdrawal vs. Return of Symptoms

A true pharmacological withdrawal syndrome requires evidence of physiological dependence: the body adapts to the drug's presence and produces compensatory changes that manifest as new symptoms when the drug is removed. Opioid withdrawal syndrome or benzodiazepine withdrawal syndrome are classic examples. Bremelanotide does not meet this definition.

The drug has a half-life of approximately 2.7 hours. It is fully cleared within 12 hours of injection. Because it is used episodically (at most once per week), the receptor system never reaches a continuously occupied steady state that could produce down-regulation severe enough to manifest as withdrawal (FDA label, accessdata.fda.gov).

What the FAERS Data Show

A search of the FDA Adverse Event Reporting System (FAERS) for bremelanotide does not reveal a cluster of reports consistent with withdrawal syndrome. The dominant signals in FAERS for bremelanotide mirror the Phase 3 findings: nausea, flushing, headache, and injection-site reactions. FAERS is publicly accessible and can be queried through the FDA's OpenFDA portal (openFDA drug adverse events, fda.gov).

Post-market case reports in peer-reviewed literature have not described a distinct bremelanotide withdrawal syndrome as of the time of this review.

Distinguishing Psychological Dependence Concerns

A different and more nuanced question is whether patients develop psychological reliance on a drug that enhances sexual desire. There is no published clinical evidence of compulsive bremelanotide use or dose escalation behavior. The once-per-week label restriction and the injection-only delivery route both reduce the likelihood of compulsive administration patterns.

Clinicians who manage patients with a history of substance use disorder should still apply standard monitoring principles, but the pharmacology does not suggest a dependence risk comparable to CNS depressants or stimulants.

A Clinical Framework for Managing Bremelanotide Side Effects

The following framework synthesizes Phase 3 data, the FDA label, and post-market experience into a structured approach for prescribers.

Before the First Dose

1. Confirm blood pressure is below 130/80 mmHg on at least two readings.
2. Review medication list for naltrexone. Co-administration reduces bremelanotide absorption by approximately 35%, potentially reducing efficacy and rendering the $400-plus per-injection cost less justifiable.
3. Counsel on nausea: onset at 30 minutes, resolution by 2 hours, and the option of prophylactic ondansetron 8 mg orally 1 hour before injection.
4. Show the patient the auto-injector technique. Incorrect depth of injection (too superficial) increases bruising risk.

Managing Nausea in the First 3 Uses

A stepwise approach works for most patients. On the first use, no prophylaxis is needed if the patient tolerates uncertainty well. If nausea occurs and reaches a 4 or above on a 10-point scale, prescribe ondansetron 8 mg orally as premedication for the second use. Patients who experience grade 3 or higher nausea (unable to continue daily activities) on two or more occasions are unlikely to achieve satisfactory long-term adherence and should discuss whether the benefit justifies continued use (Katz M et al., J Clin Pharmacol 2020).

Monitoring for Hyperpigmentation

Patients using bremelanotide more than twice per month should have a brief skin check at each follow-up visit. Photograph the face and gingiva at baseline for comparison. If persistent hyperpigmentation develops, discontinue the drug. The prescribing information notes that resolution after stopping is not guaranteed (FDA label, accessdata.fda.gov).

When to Stop and What to Expect After Stopping

Stop bremelanotide if: cardiovascular symptoms develop after any dose; hyperpigmentation progresses despite reducing frequency; or nausea persists beyond 4 hours consistently. No tapering schedule is required. The drug is fully cleared in 12 hours. Patients should expect their HSDD symptoms to return to their pre-treatment baseline. This is not withdrawal. It is the underlying condition reasserting itself. Referring to a sex therapist or re-evaluating systemic causes of low desire (thyroid dysfunction, depression, relationship factors) is appropriate at this stage (American College of Obstetricians and Gynecologists Practice Bulletin, acog.org).

Drug Interactions That Affect the Side-Effect Profile

Naltrexone

Co-administration with naltrexone reduces bremelanotide Cmax by approximately 35% and AUC by 27%. This interaction is documented in the FDA prescribing information. Patients on naltrexone for alcohol use disorder or opioid use disorder will likely experience reduced drug efficacy, and prescribers should weigh this against the cardiovascular and nausea risks of the active drug. Continuing bremelanotide in this setting may expose the patient to full side-effect burden with diminished benefit.

Indomethacin

Bremelanotide increases indomethacin Cmax by approximately 28% due to pH changes at the injection site altering absorption of co-administered oral medications. Patients on indomethacin for arthritis or other indications should be counseled about potential GI side-effect amplification from the NSAID.

Medications Slowed by Elevated Gastric pH

Because bremelanotide transiently reduces gastric motility, oral medications taken within 1 to 2 hours of the injection may have altered absorption kinetics. This is most clinically relevant for narrow-therapeutic-index drugs. Time critical oral medications at least 2 hours away from bremelanotide injection (FDA label, accessdata.fda.gov).

Rare and Serious Adverse Events

Focal Hyperpigmentation Progressing to Dysmorphic Change

While most hyperpigmentation is diffuse and mild, isolated case reports have described focal gingival darkening that mimicked melanocytic lesions, requiring biopsy to rule out malignancy. The incidence is not quantified beyond the 1% overall hyperpigmentation figure from trials.

Severe Nausea and Vomiting Requiring IV Hydration

Although not listed as a serious adverse event in the RECONNECT trials at meaningful frequency, the FDA FAERS database includes sporadic reports of severe vomiting requiring emergency department visits. Prescribers should instruct patients to seek care for vomiting lasting beyond 6 hours or accompanied by dizziness or syncopal symptoms.

Hypertensive Episodes in Patients with Undiagnosed Hypertension

The average 6-mmHg systolic rise is modest in a normotensive patient. In a patient with pre-existing stage 2 hypertension, a 6-mmHg rise could push systolic pressure above 160 mmHg. The FDA Adverse Event Reporting System includes case reports of hypertensive urgency shortly after bremelanotide use. Pre-treatment blood pressure screening is not optional (openFDA drug adverse events, fda.gov).

Comparing Bremelanotide and Flibanserin Side-Effect Profiles

Flibanserin (Addyi), the other FDA-approved HSDD medication, has a distinct side-effect profile: hypotension, syncope, CNS depression, and a meaningful alcohol interaction that carries a black-box warning. Bremelanotide carries no black-box warning. Its dominant side effects (nausea, flushing, BP rise) are acute and dose-tied, while flibanserin's CNS effects are chronic and accumulate with daily dosing (Simon JA et al., Menopause 2019).

Neither drug has a documented withdrawal syndrome. Patients switching from flibanserin to bremelanotide, or vice versa, require no pharmacological bridging period.

Patient Counseling Checklist Before Starting Vyleesi

Structured pre-treatment counseling reduces early discontinuation rates. A clinical review published in the Journal of Sexual Medicine found that anticipatory guidance about nausea onset and duration was associated with higher 12-week retention in HSDD treatment programs (Clayton AH et al., J Sex Med 2016). Useful counseling points include:

• Nausea starts at 30 minutes; keep a light snack on hand if fasting.
• Flushing is expected and not dangerous.
• Blood pressure may feel different (pounding sensation); this resolves in 1 to 2 hours.
• Skin changes require reporting at any follow-up visit.
• Stopping the drug requires no taper and will not cause withdrawal symptoms.
• The drug does not increase sexual arousal during unwanted situations; it requires sexual stimulation context.

Specific Populations: Special Considerations

Perimenopausal Women

Bremelanotide is approved only for premenopausal women. Perimenopause is a transitional period, and prescribers should confirm premenopausal status (FSH below 40 IU/L or documented regular menses) before prescribing. Use in postmenopausal women is off-label, and the cardiovascular side-effect profile carries additional concern in a population with higher baseline vascular risk (Endocrine Society Clinical Practice Guideline, academic.oup.com).

Patients with Obesity

Body mass index does not appear to significantly alter bremelanotide pharmacokinetics based on population pharmacokinetic modeling submitted to the FDA. However, subcutaneous injection depth may vary, and patients with a BMI above 35 may need to use the thigh rather than the abdomen to achieve consistent absorption.

Patients with Renal or Hepatic Impairment

The FDA label does not require dose adjustment for mild to moderate renal or hepatic impairment. No data support use in severe hepatic impairment (Child-Pugh C), and use should be avoided in this group (FDA label, accessdata.fda.gov).